[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fVjx75rMup2-btx_VUA3luJz2uiAMszvF1tUJer8Z8Js":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":35,"phaseBuckets":41,"rows":48},"ALK-Abelló A\u002FS",[4],67,false,1,35,328198,5,[13,16,19,22,25,28,30,32],{"name":14,"count":15},"Allergy",21,{"name":17,"count":18},"Allergic Rhinoconjunctivitis",11,{"name":20,"count":21},"Allergic Rhinitis",10,{"name":23,"count":24},"Conjunctivitis",7,{"name":26,"count":27},"Allergic Rhinitis Due to House Dust Mite",4,{"name":29,"count":27},"Rhinitis",{"name":31,"count":27},"Asthma",{"name":33,"count":34},"Rhinitis, Allergic, Perennial",3,[36],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT07060885","A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65","2026-09-06","HDM SLIT-tablet",[42,43,44,45,46,47],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[49,94,170,197,215,233,258,308,345,386,408,430,452,486,517,542,560,583,607,625,649,678,696,714,732,750,768,794,816,834,852,870,888,914,932,950,975,993,1015,1039,1067,1085,1103,1121,1139,1166,1190,1214,1232,1250,1268,1286,1310,1333,1356,1380,1404,1436,1458,1482,1506,1529,1551,1575,1593,1611,1642,1660,1678,1696,1714,1732,1750,1773,1798,1822,1847,1873,1894,1916,1940,1965,1990],{"intervention":40,"totalTrials":34,"cells":50},{"EARLY_PHASE1":51,"PHASE1":54,"PHASE2":56,"PHASE3":58,"PHASE4":90,"NA":92},{"trials":52,"activeCount":53},[],0,{"trials":55,"activeCount":53},[],{"trials":57,"activeCount":53},[],{"trials":59,"activeCount":8,"soonestReadout":39},[60,68,78],{"nctId":37,"briefTitle":38,"status":61,"phases":62,"primaryCompletion":39,"completion":63,"start":64,"enrollment":65,"conditions":66,"interventions":67},"ACTIVE_NOT_RECRUITING",[45],"2026-09-13","2025-09-01",327,[17,20],[40],{"nctId":69,"briefTitle":70,"status":71,"phases":72,"primaryCompletion":73,"completion":73,"start":74,"enrollment":75,"conditions":76,"interventions":77},"NCT04541004","Adolescent Mite Allergy Safety Evaluation","COMPLETED",[45],"2021-04-24","2020-09-23",253,[20,17],[40],{"nctId":79,"briefTitle":80,"status":71,"phases":81,"primaryCompletion":82,"completion":83,"start":84,"enrollment":85,"conditions":86,"interventions":89},"NCT03654976","Mite Asthma Pediatric Immunotherapy Trial",[45],"2022-05-18","2022-05-31","2018-02-22",533,[87,88,26],"Allergic Asthma Due to Dermatophagoides Farinae","Allergic Asthma Due to Dermatophagoides Pteronyssinus",[40],{"trials":91,"activeCount":53},[],{"trials":93,"activeCount":53},[],{"intervention":95,"totalTrials":96,"cells":97},"Grazax",6,{"EARLY_PHASE1":98,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":136,"NA":168},{"trials":99,"activeCount":53},[],{"trials":101,"activeCount":53},[],{"trials":103,"activeCount":53},[],{"trials":105,"activeCount":53},[106,115,126],{"nctId":107,"briefTitle":108,"status":71,"phases":109,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":114},"NCT01061203","Grazax Asthma Prevention",[45],"2015-09","2010-01",812,[20],[95],{"nctId":116,"briefTitle":117,"status":71,"phases":118,"primaryCompletion":119,"completion":120,"start":121,"enrollment":122,"conditions":123,"interventions":125},"NCT00773240","A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment",[45],"2008-10","2009-02","2008-04",276,[124],"Grass Pollen Allergy",[95],{"nctId":127,"briefTitle":128,"status":71,"phases":129,"primaryCompletion":130,"completion":131,"start":132,"enrollment":133,"conditions":134,"interventions":135},"NCT00421655","A Trial of Grazax in Subjects With Hayfever",[45],"2007-08","2007-10","2006-12",329,[14],[95],{"trials":137,"activeCount":53},[138,148,158],{"nctId":139,"briefTitle":140,"status":71,"phases":141,"primaryCompletion":142,"completion":143,"start":144,"enrollment":145,"conditions":146,"interventions":147},"NCT01433510","Tolerability of Grazax in Patients With Hayfever in Real Life Settings",[46],"2010-10","2010-12","2007-11",628,[17],[95],{"nctId":149,"briefTitle":150,"status":71,"phases":151,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":155,"interventions":156},"NCT02437786","Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®",[46],"2014-12","2009-09",58,[17],[157],"GRAZAX",{"nctId":159,"briefTitle":160,"status":71,"phases":161,"primaryCompletion":162,"completion":162,"start":163,"enrollment":164,"conditions":165,"interventions":167},"NCT01854736","Molecular and Cellular Mechanism in the Course of Immunotherapy With a Phleum Pratense Oral Lyophilisate",[46],"2015-12","2013-04",51,[166],"Allergic Rhinitis Due to Grass Pollens",[95],{"trials":169,"activeCount":53},[],{"intervention":171,"totalTrials":8,"cells":172},"MK-3641 12 Amb a 1-U",{"EARLY_PHASE1":173,"PHASE1":175,"PHASE2":177,"PHASE3":179,"PHASE4":181,"NA":195},{"trials":174,"activeCount":53},[],{"trials":176,"activeCount":53},[],{"trials":178,"activeCount":53},[],{"trials":180,"activeCount":53},[],{"trials":182,"activeCount":53},[183],{"nctId":184,"briefTitle":185,"status":71,"phases":186,"primaryCompletion":187,"completion":187,"start":188,"enrollment":189,"conditions":190,"interventions":192},"NCT02256553","Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)",[46],"2015-02","2014-10",102,[191],"Rhinitis, Allergic, Seasonal",[171,193,194],"MK-7243 2800 BAU","Rescue Medication",{"trials":196,"activeCount":53},[],{"intervention":193,"totalTrials":8,"cells":198},{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":203,"PHASE3":205,"PHASE4":207,"NA":213},{"trials":200,"activeCount":53},[],{"trials":202,"activeCount":53},[],{"trials":204,"activeCount":53},[],{"trials":206,"activeCount":53},[],{"trials":208,"activeCount":53},[209],{"nctId":184,"briefTitle":185,"status":71,"phases":210,"primaryCompletion":187,"completion":187,"start":188,"enrollment":189,"conditions":211,"interventions":212},[46],[191],[171,193,194],{"trials":214,"activeCount":53},[],{"intervention":194,"totalTrials":8,"cells":216},{"EARLY_PHASE1":217,"PHASE1":219,"PHASE2":221,"PHASE3":223,"PHASE4":225,"NA":231},{"trials":218,"activeCount":53},[],{"trials":220,"activeCount":53},[],{"trials":222,"activeCount":53},[],{"trials":224,"activeCount":53},[],{"trials":226,"activeCount":53},[227],{"nctId":184,"briefTitle":185,"status":71,"phases":228,"primaryCompletion":187,"completion":187,"start":188,"enrollment":189,"conditions":229,"interventions":230},[46],[191],[171,193,194],{"trials":232,"activeCount":53},[],{"intervention":234,"totalTrials":8,"cells":235},"Pangramin Plus D. pteronyssinus 100%",{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":240,"PHASE3":242,"PHASE4":244,"NA":256},{"trials":237,"activeCount":53},[],{"trials":239,"activeCount":53},[],{"trials":241,"activeCount":53},[],{"trials":243,"activeCount":53},[],{"trials":245,"activeCount":53},[246],{"nctId":247,"briefTitle":248,"status":71,"phases":249,"primaryCompletion":250,"completion":250,"start":251,"enrollment":252,"conditions":253,"interventions":255},"NCT00492076","Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma",[46],"2008-05","2006-10",45,[254],"Allergic Asthma",[234],{"trials":257,"activeCount":53},[],{"intervention":259,"totalTrials":27,"cells":260},"ALK Grass",{"EARLY_PHASE1":261,"PHASE1":263,"PHASE2":283,"PHASE3":285,"PHASE4":304,"NA":306},{"trials":262,"activeCount":53},[],{"trials":264,"activeCount":53},[265,274],{"nctId":266,"briefTitle":267,"status":71,"phases":268,"completion":269,"start":270,"enrollment":271,"conditions":272,"interventions":273},"NCT00298701","Tolerability of Grazax-R in Children",[43],"2006-04","2006-02",50,[14],[259],{"nctId":275,"briefTitle":276,"status":71,"phases":277,"completion":278,"start":279,"enrollment":280,"conditions":281,"interventions":282},"NCT00310453","Tolerability of ALK Grass Tablet in Children",[43],"2006-05","2006-03",32,[14],[259],{"trials":284,"activeCount":53},[],{"trials":286,"activeCount":53},[287,295],{"nctId":288,"briefTitle":289,"status":71,"phases":290,"primaryCompletion":153,"completion":153,"start":291,"enrollment":292,"conditions":293,"interventions":294},"NCT00227279","A Trial of the ALK Grass Tablet in Subjects With Hayfever",[45],"2004-10",634,[14],[259],{"nctId":296,"briefTitle":297,"status":71,"phases":298,"primaryCompletion":130,"completion":299,"start":300,"enrollment":301,"conditions":302,"interventions":303},"NCT00413556","Changes in the Immune Response and Skin Reactivity of Grass Pollen Allergic Patients Treated With ALK Grass Tablets",[45],"2007-12","2007-01",76,[14],[259],{"trials":305,"activeCount":53},[],{"trials":307,"activeCount":53},[],{"intervention":309,"totalTrials":310,"cells":311},"AVANZ Phleum pratense",2,{"EARLY_PHASE1":312,"PHASE1":314,"PHASE2":316,"PHASE3":318,"PHASE4":341,"NA":343},{"trials":313,"activeCount":53},[],{"trials":315,"activeCount":53},[],{"trials":317,"activeCount":53},[],{"trials":319,"activeCount":53},[320,330],{"nctId":321,"briefTitle":322,"status":71,"phases":323,"primaryCompletion":324,"completion":325,"start":326,"enrollment":327,"conditions":328,"interventions":329},"NCT01454531","An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy",[44,45],"2012-03","2012-04","2011-06",199,[17],[309],{"nctId":331,"briefTitle":332,"status":71,"phases":333,"primaryCompletion":334,"completion":335,"start":336,"enrollment":337,"conditions":338,"interventions":339},"NCT01438827","Avanz Phleum Pratense Maintenance Dose",[44,45],"2012-12","2013-01","2011-09",450,[17],[340],"Avanz Phleum pratense",{"trials":342,"activeCount":53},[],{"trials":344,"activeCount":53},[],{"intervention":346,"totalTrials":310,"cells":347},"SCH 697243",{"EARLY_PHASE1":348,"PHASE1":350,"PHASE2":352,"PHASE3":354,"PHASE4":382,"NA":384},{"trials":349,"activeCount":53},[],{"trials":351,"activeCount":53},[],{"trials":353,"activeCount":53},[],{"trials":355,"activeCount":53},[356,371],{"nctId":357,"briefTitle":358,"status":71,"phases":359,"primaryCompletion":153,"completion":153,"start":144,"enrollment":360,"conditions":361,"interventions":363},"NCT00550550","Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)",[45],345,[362,29,23,14],"Rhinoconjunctivitis",[346,364,365,366,367,368,369,370],"Loratadine Syrup 1 mg\u002FmL Rescue Treatment","Loratadine 10 mg Rescue Treatment","Olopatadine 0.1% Rescue Treatment","Mometasone furoate 50 mcg Rescue Treatment","Albuterol 108 mcg Rescue Treatment","Fluticasone 44 mcg Rescue Treatment","Prednisone 5 mg Rescue Treatment",{"nctId":372,"briefTitle":373,"status":71,"phases":374,"primaryCompletion":153,"completion":153,"start":144,"enrollment":375,"conditions":376,"interventions":377},"NCT00562159","Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)",[45],439,[362,29,23,14],[346,365,366,378,370,379,380,381],"Mometasone 50 mcg Rescue Treatment","Albuterol sulfate 108 mcg","Fluticasone propionate 44 mcg","Prednisone 5 mg",{"trials":383,"activeCount":53},[],{"trials":385,"activeCount":53},[],{"intervention":365,"totalTrials":310,"cells":387},{"EARLY_PHASE1":388,"PHASE1":390,"PHASE2":392,"PHASE3":394,"PHASE4":404,"NA":406},{"trials":389,"activeCount":53},[],{"trials":391,"activeCount":53},[],{"trials":393,"activeCount":53},[],{"trials":395,"activeCount":53},[396,400],{"nctId":357,"briefTitle":358,"status":71,"phases":397,"primaryCompletion":153,"completion":153,"start":144,"enrollment":360,"conditions":398,"interventions":399},[45],[362,29,23,14],[346,364,365,366,367,368,369,370],{"nctId":372,"briefTitle":373,"status":71,"phases":401,"primaryCompletion":153,"completion":153,"start":144,"enrollment":375,"conditions":402,"interventions":403},[45],[362,29,23,14],[346,365,366,378,370,379,380,381],{"trials":405,"activeCount":53},[],{"trials":407,"activeCount":53},[],{"intervention":366,"totalTrials":310,"cells":409},{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":416,"PHASE4":426,"NA":428},{"trials":411,"activeCount":53},[],{"trials":413,"activeCount":53},[],{"trials":415,"activeCount":53},[],{"trials":417,"activeCount":53},[418,422],{"nctId":357,"briefTitle":358,"status":71,"phases":419,"primaryCompletion":153,"completion":153,"start":144,"enrollment":360,"conditions":420,"interventions":421},[45],[362,29,23,14],[346,364,365,366,367,368,369,370],{"nctId":372,"briefTitle":373,"status":71,"phases":423,"primaryCompletion":153,"completion":153,"start":144,"enrollment":375,"conditions":424,"interventions":425},[45],[362,29,23,14],[346,365,366,378,370,379,380,381],{"trials":427,"activeCount":53},[],{"trials":429,"activeCount":53},[],{"intervention":370,"totalTrials":310,"cells":431},{"EARLY_PHASE1":432,"PHASE1":434,"PHASE2":436,"PHASE3":438,"PHASE4":448,"NA":450},{"trials":433,"activeCount":53},[],{"trials":435,"activeCount":53},[],{"trials":437,"activeCount":53},[],{"trials":439,"activeCount":53},[440,444],{"nctId":357,"briefTitle":358,"status":71,"phases":441,"primaryCompletion":153,"completion":153,"start":144,"enrollment":360,"conditions":442,"interventions":443},[45],[362,29,23,14],[346,364,365,366,367,368,369,370],{"nctId":372,"briefTitle":373,"status":71,"phases":445,"primaryCompletion":153,"completion":153,"start":144,"enrollment":375,"conditions":446,"interventions":447},[45],[362,29,23,14],[346,365,366,378,370,379,380,381],{"trials":449,"activeCount":53},[],{"trials":451,"activeCount":53},[],{"intervention":453,"totalTrials":310,"cells":454},"subcutaneous immunotherapy",{"EARLY_PHASE1":455,"PHASE1":457,"PHASE2":459,"PHASE3":470,"PHASE4":482,"NA":484},{"trials":456,"activeCount":53},[],{"trials":458,"activeCount":53},[],{"trials":460,"activeCount":53},[461],{"nctId":462,"briefTitle":463,"status":71,"phases":464,"primaryCompletion":465,"completion":466,"start":120,"enrollment":467,"conditions":468,"interventions":469},"NCT00857779","Study on Pharmacodynamic Parameter and Tolerability With Subcutaneous Immunotherapy in Grass Pollen Allergic Patients",[44],"2009-08","2009-10",473,[29,23,31],[453],{"trials":471,"activeCount":53},[472],{"nctId":473,"briefTitle":474,"status":71,"phases":475,"primaryCompletion":476,"completion":477,"start":269,"enrollment":478,"conditions":479,"interventions":481},"NCT00310492","Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic Dermatitis",[45],"2009-05","2009-11",154,[480],"Atopic Dermatitis",[453],{"trials":483,"activeCount":53},[],{"trials":485,"activeCount":53},[],{"intervention":487,"totalTrials":310,"cells":488},"SCH 39641",{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":503,"PHASE4":513,"NA":515},{"trials":490,"activeCount":53},[],{"trials":492,"activeCount":53},[],{"trials":494,"activeCount":53},[495],{"nctId":496,"briefTitle":497,"status":71,"phases":498,"primaryCompletion":499,"completion":499,"start":477,"enrollment":500,"conditions":501,"interventions":502},"NCT00978029","Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)",[44],"2010-02",203,[362,29,23,14],[487,487],{"trials":504,"activeCount":53},[505],{"nctId":506,"briefTitle":507,"status":71,"phases":508,"primaryCompletion":325,"completion":325,"start":509,"enrollment":510,"conditions":511,"interventions":512},"NCT01469182","A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)",[45],"2011-11",914,[14],[487],{"trials":514,"activeCount":53},[],{"trials":516,"activeCount":53},[],{"intervention":518,"totalTrials":8,"cells":519},"Grazax + Aerius",{"EARLY_PHASE1":520,"PHASE1":522,"PHASE2":524,"PHASE3":526,"PHASE4":538,"NA":540},{"trials":521,"activeCount":53},[],{"trials":523,"activeCount":53},[],{"trials":525,"activeCount":53},[],{"trials":527,"activeCount":53},[528],{"nctId":529,"briefTitle":530,"status":71,"phases":531,"primaryCompletion":532,"completion":532,"start":533,"enrollment":534,"conditions":535,"interventions":536},"NCT01740284","A Trial Evaluating Tolerability of Grazax Treatment in Combination With Antihistamine",[45],"2009-01","2008-09",46,[17],[518,537],"Grazax + placebo",{"trials":539,"activeCount":53},[],{"trials":541,"activeCount":53},[],{"intervention":537,"totalTrials":8,"cells":543},{"EARLY_PHASE1":544,"PHASE1":546,"PHASE2":548,"PHASE3":550,"PHASE4":556,"NA":558},{"trials":545,"activeCount":53},[],{"trials":547,"activeCount":53},[],{"trials":549,"activeCount":53},[],{"trials":551,"activeCount":53},[552],{"nctId":529,"briefTitle":530,"status":71,"phases":553,"primaryCompletion":532,"completion":532,"start":533,"enrollment":534,"conditions":554,"interventions":555},[45],[17],[518,537],{"trials":557,"activeCount":53},[],{"trials":559,"activeCount":53},[],{"intervention":561,"totalTrials":8,"cells":562},"Pangramin SLIT HDM mix.",{"EARLY_PHASE1":563,"PHASE1":565,"PHASE2":567,"PHASE3":569,"PHASE4":579,"NA":581},{"trials":564,"activeCount":53},[],{"trials":566,"activeCount":53},[],{"trials":568,"activeCount":53},[],{"trials":570,"activeCount":53},[571],{"nctId":572,"briefTitle":573,"status":71,"phases":574,"primaryCompletion":575,"completion":575,"start":466,"enrollment":576,"conditions":577,"interventions":578},"NCT01603056","Efficacy and Safety Trial of Pangramin SLIT HDM-mix in Subjects With House Dust Mite Induced Rhinitis",[45],"2012-02",617,[20],[561],{"trials":580,"activeCount":53},[],{"trials":582,"activeCount":53},[],{"intervention":584,"totalTrials":8,"cells":585},"Grazax-R",{"EARLY_PHASE1":586,"PHASE1":588,"PHASE2":590,"PHASE3":592,"PHASE4":603,"NA":605},{"trials":587,"activeCount":53},[],{"trials":589,"activeCount":53},[],{"trials":591,"activeCount":53},[],{"trials":593,"activeCount":53},[594],{"nctId":595,"briefTitle":596,"status":71,"phases":597,"primaryCompletion":598,"completion":144,"start":599,"enrollment":75,"conditions":600,"interventions":601},"NCT00408616","Efficacy and Safety of Grazax in Children",[45],"2007-09","2006-11",[14],[584,602],"Grazax Placebo",{"trials":604,"activeCount":53},[],{"trials":606,"activeCount":53},[],{"intervention":602,"totalTrials":8,"cells":608},{"EARLY_PHASE1":609,"PHASE1":611,"PHASE2":613,"PHASE3":615,"PHASE4":621,"NA":623},{"trials":610,"activeCount":53},[],{"trials":612,"activeCount":53},[],{"trials":614,"activeCount":53},[],{"trials":616,"activeCount":53},[617],{"nctId":595,"briefTitle":596,"status":71,"phases":618,"primaryCompletion":598,"completion":144,"start":599,"enrollment":75,"conditions":619,"interventions":620},[45],[14],[584,602],{"trials":622,"activeCount":53},[],{"trials":624,"activeCount":53},[],{"intervention":626,"totalTrials":8,"cells":627},"Sublingual immunotherapy",{"EARLY_PHASE1":628,"PHASE1":630,"PHASE2":632,"PHASE3":634,"PHASE4":645,"NA":647},{"trials":629,"activeCount":53},[],{"trials":631,"activeCount":53},[],{"trials":633,"activeCount":53},[],{"trials":635,"activeCount":53},[636],{"nctId":637,"briefTitle":638,"status":71,"phases":639,"primaryCompletion":640,"completion":300,"start":641,"enrollment":642,"conditions":643,"interventions":644},"NCT00310466","Efficacy and Safety Trial of SLITone(TM) Birch in Subjects With Hayfever",[45],"2006-08","2005-06",226,[14],[626],{"trials":646,"activeCount":53},[],{"trials":648,"activeCount":53},[],{"intervention":650,"totalTrials":8,"cells":651},"SLITone(TM) Dermatophagoides mix",{"EARLY_PHASE1":652,"PHASE1":654,"PHASE2":656,"PHASE3":658,"PHASE4":674,"NA":676},{"trials":653,"activeCount":53},[],{"trials":655,"activeCount":53},[],{"trials":657,"activeCount":53},[],{"trials":659,"activeCount":53},[660],{"nctId":661,"briefTitle":662,"status":71,"phases":663,"primaryCompletion":664,"completion":120,"start":665,"enrollment":666,"conditions":667,"interventions":668},"NCT00633919","Efficacy of SLITone in House Dust Mite Allergic Patients",[44,45],"2008-12","2006-07",124,[14],[650,669,670,671,672,673],"Salbutamol inhaler","Budesonide\u002Fformoterol inhaler","Prednisone","Desloratadine","Budesonide nasal spray",{"trials":675,"activeCount":53},[],{"trials":677,"activeCount":53},[],{"intervention":669,"totalTrials":8,"cells":679},{"EARLY_PHASE1":680,"PHASE1":682,"PHASE2":684,"PHASE3":686,"PHASE4":692,"NA":694},{"trials":681,"activeCount":53},[],{"trials":683,"activeCount":53},[],{"trials":685,"activeCount":53},[],{"trials":687,"activeCount":53},[688],{"nctId":661,"briefTitle":662,"status":71,"phases":689,"primaryCompletion":664,"completion":120,"start":665,"enrollment":666,"conditions":690,"interventions":691},[44,45],[14],[650,669,670,671,672,673],{"trials":693,"activeCount":53},[],{"trials":695,"activeCount":53},[],{"intervention":670,"totalTrials":8,"cells":697},{"EARLY_PHASE1":698,"PHASE1":700,"PHASE2":702,"PHASE3":704,"PHASE4":710,"NA":712},{"trials":699,"activeCount":53},[],{"trials":701,"activeCount":53},[],{"trials":703,"activeCount":53},[],{"trials":705,"activeCount":53},[706],{"nctId":661,"briefTitle":662,"status":71,"phases":707,"primaryCompletion":664,"completion":120,"start":665,"enrollment":666,"conditions":708,"interventions":709},[44,45],[14],[650,669,670,671,672,673],{"trials":711,"activeCount":53},[],{"trials":713,"activeCount":53},[],{"intervention":671,"totalTrials":8,"cells":715},{"EARLY_PHASE1":716,"PHASE1":718,"PHASE2":720,"PHASE3":722,"PHASE4":728,"NA":730},{"trials":717,"activeCount":53},[],{"trials":719,"activeCount":53},[],{"trials":721,"activeCount":53},[],{"trials":723,"activeCount":53},[724],{"nctId":661,"briefTitle":662,"status":71,"phases":725,"primaryCompletion":664,"completion":120,"start":665,"enrollment":666,"conditions":726,"interventions":727},[44,45],[14],[650,669,670,671,672,673],{"trials":729,"activeCount":53},[],{"trials":731,"activeCount":53},[],{"intervention":672,"totalTrials":8,"cells":733},{"EARLY_PHASE1":734,"PHASE1":736,"PHASE2":738,"PHASE3":740,"PHASE4":746,"NA":748},{"trials":735,"activeCount":53},[],{"trials":737,"activeCount":53},[],{"trials":739,"activeCount":53},[],{"trials":741,"activeCount":53},[742],{"nctId":661,"briefTitle":662,"status":71,"phases":743,"primaryCompletion":664,"completion":120,"start":665,"enrollment":666,"conditions":744,"interventions":745},[44,45],[14],[650,669,670,671,672,673],{"trials":747,"activeCount":53},[],{"trials":749,"activeCount":53},[],{"intervention":673,"totalTrials":8,"cells":751},{"EARLY_PHASE1":752,"PHASE1":754,"PHASE2":756,"PHASE3":758,"PHASE4":764,"NA":766},{"trials":753,"activeCount":53},[],{"trials":755,"activeCount":53},[],{"trials":757,"activeCount":53},[],{"trials":759,"activeCount":53},[760],{"nctId":661,"briefTitle":662,"status":71,"phases":761,"primaryCompletion":664,"completion":120,"start":665,"enrollment":666,"conditions":762,"interventions":763},[44,45],[14],[650,669,670,671,672,673],{"trials":765,"activeCount":53},[],{"trials":767,"activeCount":53},[],{"intervention":769,"totalTrials":8,"cells":770},"Sublingual allergy immunological",{"EARLY_PHASE1":771,"PHASE1":773,"PHASE2":775,"PHASE3":777,"PHASE4":790,"NA":792},{"trials":772,"activeCount":53},[],{"trials":774,"activeCount":53},[],{"trials":776,"activeCount":53},[],{"trials":778,"activeCount":53},[779],{"nctId":780,"briefTitle":781,"status":782,"phases":783,"primaryCompletion":784,"completion":785,"start":786,"enrollment":787,"conditions":788,"interventions":789},"NCT04176185","A Research Study in Chinese People With Allergy to House Dust Mites, Using an Environmental Exposure Chamber","TERMINATED",[45],"2019-12-17","2022-01-19","2019-11-04",80,[17],[769],{"trials":791,"activeCount":53},[],{"trials":793,"activeCount":53},[],{"intervention":795,"totalTrials":8,"cells":796},"Allergy vaccination",{"EARLY_PHASE1":797,"PHASE1":799,"PHASE2":801,"PHASE3":803,"PHASE4":812,"NA":814},{"trials":798,"activeCount":53},[],{"trials":800,"activeCount":53},[],{"trials":802,"activeCount":53},[],{"trials":804,"activeCount":53},[805],{"nctId":806,"briefTitle":807,"status":71,"phases":808,"primaryCompletion":119,"completion":532,"start":121,"enrollment":809,"conditions":810,"interventions":811},"NCT00807547","Intraseasonal Short-time Up-dosing With Alutard SQ Grasses",[45],149,[14],[795],{"trials":813,"activeCount":53},[],{"trials":815,"activeCount":53},[],{"intervention":364,"totalTrials":8,"cells":817},{"EARLY_PHASE1":818,"PHASE1":820,"PHASE2":822,"PHASE3":824,"PHASE4":830,"NA":832},{"trials":819,"activeCount":53},[],{"trials":821,"activeCount":53},[],{"trials":823,"activeCount":53},[],{"trials":825,"activeCount":53},[826],{"nctId":357,"briefTitle":358,"status":71,"phases":827,"primaryCompletion":153,"completion":153,"start":144,"enrollment":360,"conditions":828,"interventions":829},[45],[362,29,23,14],[346,364,365,366,367,368,369,370],{"trials":831,"activeCount":53},[],{"trials":833,"activeCount":53},[],{"intervention":367,"totalTrials":8,"cells":835},{"EARLY_PHASE1":836,"PHASE1":838,"PHASE2":840,"PHASE3":842,"PHASE4":848,"NA":850},{"trials":837,"activeCount":53},[],{"trials":839,"activeCount":53},[],{"trials":841,"activeCount":53},[],{"trials":843,"activeCount":53},[844],{"nctId":357,"briefTitle":358,"status":71,"phases":845,"primaryCompletion":153,"completion":153,"start":144,"enrollment":360,"conditions":846,"interventions":847},[45],[362,29,23,14],[346,364,365,366,367,368,369,370],{"trials":849,"activeCount":53},[],{"trials":851,"activeCount":53},[],{"intervention":368,"totalTrials":8,"cells":853},{"EARLY_PHASE1":854,"PHASE1":856,"PHASE2":858,"PHASE3":860,"PHASE4":866,"NA":868},{"trials":855,"activeCount":53},[],{"trials":857,"activeCount":53},[],{"trials":859,"activeCount":53},[],{"trials":861,"activeCount":53},[862],{"nctId":357,"briefTitle":358,"status":71,"phases":863,"primaryCompletion":153,"completion":153,"start":144,"enrollment":360,"conditions":864,"interventions":865},[45],[362,29,23,14],[346,364,365,366,367,368,369,370],{"trials":867,"activeCount":53},[],{"trials":869,"activeCount":53},[],{"intervention":369,"totalTrials":8,"cells":871},{"EARLY_PHASE1":872,"PHASE1":874,"PHASE2":876,"PHASE3":878,"PHASE4":884,"NA":886},{"trials":873,"activeCount":53},[],{"trials":875,"activeCount":53},[],{"trials":877,"activeCount":53},[],{"trials":879,"activeCount":53},[880],{"nctId":357,"briefTitle":358,"status":71,"phases":881,"primaryCompletion":153,"completion":153,"start":144,"enrollment":360,"conditions":882,"interventions":883},[45],[362,29,23,14],[346,364,365,366,367,368,369,370],{"trials":885,"activeCount":53},[],{"trials":887,"activeCount":53},[],{"intervention":889,"totalTrials":8,"cells":890},"ALK HDM AIT Placebo",{"EARLY_PHASE1":891,"PHASE1":893,"PHASE2":895,"PHASE3":897,"PHASE4":910,"NA":912},{"trials":892,"activeCount":53},[],{"trials":894,"activeCount":53},[],{"trials":896,"activeCount":53},[],{"trials":898,"activeCount":53},[899],{"nctId":900,"briefTitle":901,"status":71,"phases":902,"primaryCompletion":163,"completion":903,"start":904,"enrollment":905,"conditions":906,"interventions":907},"NCT01433523","House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of Asthma",[45],"2014-02","2011-08",834,[31],[889,908,909],"ALK HDM AIT 6 DU","ALK HDM AIT 12 DU",{"trials":911,"activeCount":53},[],{"trials":913,"activeCount":53},[],{"intervention":908,"totalTrials":8,"cells":915},{"EARLY_PHASE1":916,"PHASE1":918,"PHASE2":920,"PHASE3":922,"PHASE4":928,"NA":930},{"trials":917,"activeCount":53},[],{"trials":919,"activeCount":53},[],{"trials":921,"activeCount":53},[],{"trials":923,"activeCount":53},[924],{"nctId":900,"briefTitle":901,"status":71,"phases":925,"primaryCompletion":163,"completion":903,"start":904,"enrollment":905,"conditions":926,"interventions":927},[45],[31],[889,908,909],{"trials":929,"activeCount":53},[],{"trials":931,"activeCount":53},[],{"intervention":909,"totalTrials":8,"cells":933},{"EARLY_PHASE1":934,"PHASE1":936,"PHASE2":938,"PHASE3":940,"PHASE4":946,"NA":948},{"trials":935,"activeCount":53},[],{"trials":937,"activeCount":53},[],{"trials":939,"activeCount":53},[],{"trials":941,"activeCount":53},[942],{"nctId":900,"briefTitle":901,"status":71,"phases":943,"primaryCompletion":163,"completion":903,"start":904,"enrollment":905,"conditions":944,"interventions":945},[45],[31],[889,908,909],{"trials":947,"activeCount":53},[],{"trials":949,"activeCount":53},[],{"intervention":951,"totalTrials":8,"cells":952},"SCH 39641 6 Amb a 1-U",{"EARLY_PHASE1":953,"PHASE1":955,"PHASE2":957,"PHASE3":959,"PHASE4":971,"NA":973},{"trials":954,"activeCount":53},[],{"trials":956,"activeCount":53},[],{"trials":958,"activeCount":53},[],{"trials":960,"activeCount":53},[961],{"nctId":962,"briefTitle":963,"status":71,"phases":964,"primaryCompletion":965,"completion":965,"start":153,"enrollment":966,"conditions":967,"interventions":969},"NCT00783198","Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)",[44,45],"2011-05",565,[968,23],"Rhinitis; Allergic, With Asthma",[951,970],"SCH 39641 12 Amb a 1-U",{"trials":972,"activeCount":53},[],{"trials":974,"activeCount":53},[],{"intervention":970,"totalTrials":8,"cells":976},{"EARLY_PHASE1":977,"PHASE1":979,"PHASE2":981,"PHASE3":983,"PHASE4":989,"NA":991},{"trials":978,"activeCount":53},[],{"trials":980,"activeCount":53},[],{"trials":982,"activeCount":53},[],{"trials":984,"activeCount":53},[985],{"nctId":962,"briefTitle":963,"status":71,"phases":986,"primaryCompletion":965,"completion":965,"start":153,"enrollment":966,"conditions":987,"interventions":988},[44,45],[968,23],[951,970],{"trials":990,"activeCount":53},[],{"trials":992,"activeCount":53},[],{"intervention":994,"totalTrials":8,"cells":995},"ALK HDM",{"EARLY_PHASE1":996,"PHASE1":998,"PHASE2":1000,"PHASE3":1002,"PHASE4":1011,"NA":1013},{"trials":997,"activeCount":53},[],{"trials":999,"activeCount":53},[],{"trials":1001,"activeCount":53},[],{"trials":1003,"activeCount":53},[1004],{"nctId":1005,"briefTitle":1006,"status":71,"phases":1007,"primaryCompletion":121,"completion":121,"start":640,"enrollment":1008,"conditions":1009,"interventions":1010},"NCT00389363","Efficacy and Safety Trial of the ALK HDM Tablet in House Dust Mite Allergic Subjects",[44,45],800,[31],[994],{"trials":1012,"activeCount":53},[],{"trials":1014,"activeCount":53},[],{"intervention":1016,"totalTrials":8,"cells":1017},"AVANZ olea",{"EARLY_PHASE1":1018,"PHASE1":1020,"PHASE2":1022,"PHASE3":1024,"PHASE4":1035,"NA":1037},{"trials":1019,"activeCount":53},[],{"trials":1021,"activeCount":53},[],{"trials":1023,"activeCount":53},[],{"trials":1025,"activeCount":53},[1026],{"nctId":1027,"briefTitle":1028,"status":71,"phases":1029,"primaryCompletion":163,"completion":163,"start":1030,"enrollment":1031,"conditions":1032,"interventions":1034},"NCT01674595","An Open Trial to Assess the Tolerability of AVANZ Olive Immunotherapy",[44,45],"2012-09",93,[1033],"Allergic Rhinitis Due to Olea Europaea Pollen",[1016],{"trials":1036,"activeCount":53},[],{"trials":1038,"activeCount":53},[],{"intervention":1040,"totalTrials":8,"cells":1041},"MK-8237",{"EARLY_PHASE1":1042,"PHASE1":1044,"PHASE2":1046,"PHASE3":1048,"PHASE4":1063,"NA":1065},{"trials":1043,"activeCount":53},[],{"trials":1045,"activeCount":53},[],{"trials":1047,"activeCount":53},[],{"trials":1049,"activeCount":53},[1050],{"nctId":1051,"briefTitle":1052,"status":71,"phases":1053,"primaryCompletion":1054,"completion":1054,"start":335,"enrollment":1055,"conditions":1056,"interventions":1058},"NCT01700192","Efficacy and Safety Study of SCH 900237\u002FMK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis\u002FRhinoconjunctivitis (P05607)",[45],"2015-04",1482,[33,1057],"Rhinitis, Allergic, Nonseasonal",[1040,1059,1060,1061,1062],"Rescue Medication: Self-Injectable Epinephrine","Rescue Medication: Loratadine","Rescue Medication: Olopatadine ophthalmic drops","Rescue Medication: Mometasone furoate nasal spray",{"trials":1064,"activeCount":53},[],{"trials":1066,"activeCount":53},[],{"intervention":1059,"totalTrials":8,"cells":1068},{"EARLY_PHASE1":1069,"PHASE1":1071,"PHASE2":1073,"PHASE3":1075,"PHASE4":1081,"NA":1083},{"trials":1070,"activeCount":53},[],{"trials":1072,"activeCount":53},[],{"trials":1074,"activeCount":53},[],{"trials":1076,"activeCount":53},[1077],{"nctId":1051,"briefTitle":1052,"status":71,"phases":1078,"primaryCompletion":1054,"completion":1054,"start":335,"enrollment":1055,"conditions":1079,"interventions":1080},[45],[33,1057],[1040,1059,1060,1061,1062],{"trials":1082,"activeCount":53},[],{"trials":1084,"activeCount":53},[],{"intervention":1060,"totalTrials":8,"cells":1086},{"EARLY_PHASE1":1087,"PHASE1":1089,"PHASE2":1091,"PHASE3":1093,"PHASE4":1099,"NA":1101},{"trials":1088,"activeCount":53},[],{"trials":1090,"activeCount":53},[],{"trials":1092,"activeCount":53},[],{"trials":1094,"activeCount":53},[1095],{"nctId":1051,"briefTitle":1052,"status":71,"phases":1096,"primaryCompletion":1054,"completion":1054,"start":335,"enrollment":1055,"conditions":1097,"interventions":1098},[45],[33,1057],[1040,1059,1060,1061,1062],{"trials":1100,"activeCount":53},[],{"trials":1102,"activeCount":53},[],{"intervention":1061,"totalTrials":8,"cells":1104},{"EARLY_PHASE1":1105,"PHASE1":1107,"PHASE2":1109,"PHASE3":1111,"PHASE4":1117,"NA":1119},{"trials":1106,"activeCount":53},[],{"trials":1108,"activeCount":53},[],{"trials":1110,"activeCount":53},[],{"trials":1112,"activeCount":53},[1113],{"nctId":1051,"briefTitle":1052,"status":71,"phases":1114,"primaryCompletion":1054,"completion":1054,"start":335,"enrollment":1055,"conditions":1115,"interventions":1116},[45],[33,1057],[1040,1059,1060,1061,1062],{"trials":1118,"activeCount":53},[],{"trials":1120,"activeCount":53},[],{"intervention":1062,"totalTrials":8,"cells":1122},{"EARLY_PHASE1":1123,"PHASE1":1125,"PHASE2":1127,"PHASE3":1129,"PHASE4":1135,"NA":1137},{"trials":1124,"activeCount":53},[],{"trials":1126,"activeCount":53},[],{"trials":1128,"activeCount":53},[],{"trials":1130,"activeCount":53},[1131],{"nctId":1051,"briefTitle":1052,"status":71,"phases":1132,"primaryCompletion":1054,"completion":1054,"start":335,"enrollment":1055,"conditions":1133,"interventions":1134},[45],[33,1057],[1040,1059,1060,1061,1062],{"trials":1136,"activeCount":53},[],{"trials":1138,"activeCount":53},[],{"intervention":1140,"totalTrials":8,"cells":1141},"Sublingual allergy immunotherapy",{"EARLY_PHASE1":1142,"PHASE1":1144,"PHASE2":1146,"PHASE3":1148,"PHASE4":1162,"NA":1164},{"trials":1143,"activeCount":53},[],{"trials":1145,"activeCount":53},[],{"trials":1147,"activeCount":53},[],{"trials":1149,"activeCount":53},[1150],{"nctId":1151,"briefTitle":1152,"status":71,"phases":1153,"primaryCompletion":1154,"completion":1155,"start":1156,"enrollment":1157,"conditions":1158,"interventions":1161},"NCT04145219","House Dust Mite Allergy Trial In Children",[45],"2023-04-01","2023-04-21","2019-10-12",1460,[1159,1160,26],"Allergic Rhinitis Due to Dermatophagoides Farinae","Allergic Rhinitis Due to Dermatophagoides Pteronyssinus",[1140],{"trials":1163,"activeCount":53},[],{"trials":1165,"activeCount":53},[],{"intervention":1167,"totalTrials":8,"cells":1168},"5-grass mix SLIT-drops",{"EARLY_PHASE1":1169,"PHASE1":1171,"PHASE2":1173,"PHASE3":1175,"PHASE4":1186,"NA":1188},{"trials":1170,"activeCount":53},[],{"trials":1172,"activeCount":53},[],{"trials":1174,"activeCount":53},[],{"trials":1176,"activeCount":53},[1177],{"nctId":1178,"briefTitle":1179,"status":71,"phases":1180,"primaryCompletion":1181,"completion":1181,"start":1182,"enrollment":1183,"conditions":1184,"interventions":1185},"NCT04881461","A Study in Adults With Grass Pollen-induced Rhinoconjunctivitis",[45],"2023-09-26","2021-05-10",445,[14],[1167],{"trials":1187,"activeCount":53},[],{"trials":1189,"activeCount":53},[],{"intervention":1191,"totalTrials":8,"cells":1192},"Tree SLIT-tablet",{"EARLY_PHASE1":1193,"PHASE1":1195,"PHASE2":1197,"PHASE3":1199,"PHASE4":1210,"NA":1212},{"trials":1194,"activeCount":53},[],{"trials":1196,"activeCount":53},[],{"trials":1198,"activeCount":53},[],{"trials":1200,"activeCount":53},[1201],{"nctId":1202,"briefTitle":1203,"status":71,"phases":1204,"primaryCompletion":1205,"completion":1205,"start":1206,"enrollment":1207,"conditions":1208,"interventions":1209},"NCT04878354","A Study in Children and Adolescents With Birch Pollen-induced Rhinoconjunctivitis",[45],"2023-07-31","2021-04-07",952,[14],[1191],{"trials":1211,"activeCount":53},[],{"trials":1213,"activeCount":53},[],{"intervention":378,"totalTrials":8,"cells":1215},{"EARLY_PHASE1":1216,"PHASE1":1218,"PHASE2":1220,"PHASE3":1222,"PHASE4":1228,"NA":1230},{"trials":1217,"activeCount":53},[],{"trials":1219,"activeCount":53},[],{"trials":1221,"activeCount":53},[],{"trials":1223,"activeCount":53},[1224],{"nctId":372,"briefTitle":373,"status":71,"phases":1225,"primaryCompletion":153,"completion":153,"start":144,"enrollment":375,"conditions":1226,"interventions":1227},[45],[362,29,23,14],[346,365,366,378,370,379,380,381],{"trials":1229,"activeCount":53},[],{"trials":1231,"activeCount":53},[],{"intervention":379,"totalTrials":8,"cells":1233},{"EARLY_PHASE1":1234,"PHASE1":1236,"PHASE2":1238,"PHASE3":1240,"PHASE4":1246,"NA":1248},{"trials":1235,"activeCount":53},[],{"trials":1237,"activeCount":53},[],{"trials":1239,"activeCount":53},[],{"trials":1241,"activeCount":53},[1242],{"nctId":372,"briefTitle":373,"status":71,"phases":1243,"primaryCompletion":153,"completion":153,"start":144,"enrollment":375,"conditions":1244,"interventions":1245},[45],[362,29,23,14],[346,365,366,378,370,379,380,381],{"trials":1247,"activeCount":53},[],{"trials":1249,"activeCount":53},[],{"intervention":380,"totalTrials":8,"cells":1251},{"EARLY_PHASE1":1252,"PHASE1":1254,"PHASE2":1256,"PHASE3":1258,"PHASE4":1264,"NA":1266},{"trials":1253,"activeCount":53},[],{"trials":1255,"activeCount":53},[],{"trials":1257,"activeCount":53},[],{"trials":1259,"activeCount":53},[1260],{"nctId":372,"briefTitle":373,"status":71,"phases":1261,"primaryCompletion":153,"completion":153,"start":144,"enrollment":375,"conditions":1262,"interventions":1263},[45],[362,29,23,14],[346,365,366,378,370,379,380,381],{"trials":1265,"activeCount":53},[],{"trials":1267,"activeCount":53},[],{"intervention":381,"totalTrials":8,"cells":1269},{"EARLY_PHASE1":1270,"PHASE1":1272,"PHASE2":1274,"PHASE3":1276,"PHASE4":1282,"NA":1284},{"trials":1271,"activeCount":53},[],{"trials":1273,"activeCount":53},[],{"trials":1275,"activeCount":53},[],{"trials":1277,"activeCount":53},[1278],{"nctId":372,"briefTitle":373,"status":71,"phases":1279,"primaryCompletion":153,"completion":153,"start":144,"enrollment":375,"conditions":1280,"interventions":1281},[45],[362,29,23,14],[346,365,366,378,370,379,380,381],{"trials":1283,"activeCount":53},[],{"trials":1285,"activeCount":53},[],{"intervention":1287,"totalTrials":8,"cells":1288},"AVANZ MITE",{"EARLY_PHASE1":1289,"PHASE1":1291,"PHASE2":1293,"PHASE3":1295,"PHASE4":1306,"NA":1308},{"trials":1290,"activeCount":53},[],{"trials":1292,"activeCount":53},[],{"trials":1294,"activeCount":53},[],{"trials":1296,"activeCount":53},[1297],{"nctId":1298,"briefTitle":1299,"status":71,"phases":1300,"primaryCompletion":1301,"completion":1301,"start":1302,"enrollment":189,"conditions":1303,"interventions":1305},"NCT01568190","An Open Trial to Assess the Tolerability of AVANZ Mite Mix Immunotherapy",[44,45],"2012-07","2011-12",[1304],"Allergic Rhinitis Due to Dust Mite",[1287],{"trials":1307,"activeCount":53},[],{"trials":1309,"activeCount":53},[],{"intervention":1311,"totalTrials":8,"cells":1312},"ALK Grass tablet - use of compliance device",{"EARLY_PHASE1":1313,"PHASE1":1315,"PHASE2":1317,"PHASE3":1319,"PHASE4":1329,"NA":1331},{"trials":1314,"activeCount":53},[],{"trials":1316,"activeCount":53},[],{"trials":1318,"activeCount":53},[],{"trials":1320,"activeCount":53},[1321],{"nctId":1322,"briefTitle":1323,"status":71,"phases":1324,"primaryCompletion":1325,"completion":131,"start":270,"enrollment":1326,"conditions":1327,"interventions":1328},"NCT00293046","Assessment of Grazax® Treatment Compliance",[45],"2006-09",500,[14],[1311],{"trials":1330,"activeCount":53},[],{"trials":1332,"activeCount":53},[],{"intervention":1334,"totalTrials":8,"cells":1335},"Ambrosia artemisiifolia allergen extract",{"EARLY_PHASE1":1336,"PHASE1":1338,"PHASE2":1340,"PHASE3":1342,"PHASE4":1352,"NA":1354},{"trials":1337,"activeCount":53},[],{"trials":1339,"activeCount":53},[],{"trials":1341,"activeCount":53},[],{"trials":1343,"activeCount":53},[1344],{"nctId":1345,"briefTitle":1346,"status":71,"phases":1347,"primaryCompletion":965,"completion":965,"start":153,"enrollment":1348,"conditions":1349,"interventions":1351},"NCT00770315","Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)",[44,45],784,[1350,23],"Rhinitis, Allergic",[1334],{"trials":1353,"activeCount":53},[],{"trials":1355,"activeCount":53},[],{"intervention":1357,"totalTrials":8,"cells":1358},"Grass (Phleum pratense) pollen allergen extract",{"EARLY_PHASE1":1359,"PHASE1":1361,"PHASE2":1363,"PHASE3":1365,"PHASE4":1376,"NA":1378},{"trials":1360,"activeCount":53},[],{"trials":1362,"activeCount":53},[],{"trials":1364,"activeCount":53},[],{"trials":1366,"activeCount":53},[1367],{"nctId":1368,"briefTitle":1369,"status":71,"phases":1370,"primaryCompletion":1371,"completion":1371,"start":326,"enrollment":1372,"conditions":1373,"interventions":1375},"NCT01385371","A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)",[45],"2012-08",1501,[1374,23],"Rhinitis Allergic",[1357],{"trials":1377,"activeCount":53},[],{"trials":1379,"activeCount":53},[],{"intervention":1381,"totalTrials":8,"cells":1382},"AIT",{"EARLY_PHASE1":1383,"PHASE1":1385,"PHASE2":1387,"PHASE3":1389,"PHASE4":1400,"NA":1402},{"trials":1384,"activeCount":53},[],{"trials":1386,"activeCount":53},[],{"trials":1388,"activeCount":53},[],{"trials":1390,"activeCount":53},[1391],{"nctId":1392,"briefTitle":1393,"status":71,"phases":1394,"primaryCompletion":163,"completion":163,"start":1395,"enrollment":1396,"conditions":1397,"interventions":1399},"NCT01454544","A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy Tablet",[45],"2011-10",992,[1398],"House Dust Mite Allergy",[1381],{"trials":1401,"activeCount":53},[],{"trials":1403,"activeCount":53},[],{"intervention":1405,"totalTrials":310,"cells":1406},"MK-8237 6 DU",{"EARLY_PHASE1":1407,"PHASE1":1409,"PHASE2":1421,"PHASE3":1430,"PHASE4":1432,"NA":1434},{"trials":1408,"activeCount":53},[],{"trials":1410,"activeCount":53},[1411],{"nctId":1412,"briefTitle":1413,"status":71,"phases":1414,"primaryCompletion":1415,"completion":1415,"start":1416,"enrollment":1417,"conditions":1418,"interventions":1419},"NCT01678807","Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)",[43],"2013-05","2012-10",195,[33,1057],[1405,1420],"MK-8237 12 DU",{"trials":1422,"activeCount":53},[1423],{"nctId":1424,"briefTitle":1425,"status":71,"phases":1426,"primaryCompletion":1427,"completion":1427,"start":1416,"enrollment":666,"conditions":1428,"interventions":1429},"NCT01644617","A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis\u002FRhinoconjunctivitis in Adults (MK-8237-003\u002FP07627)",[44],"2013-08",[33,1057],[1405,1420],{"trials":1431,"activeCount":53},[],{"trials":1433,"activeCount":53},[],{"trials":1435,"activeCount":53},[],{"intervention":1420,"totalTrials":310,"cells":1437},{"EARLY_PHASE1":1438,"PHASE1":1440,"PHASE2":1446,"PHASE3":1452,"PHASE4":1454,"NA":1456},{"trials":1439,"activeCount":53},[],{"trials":1441,"activeCount":53},[1442],{"nctId":1412,"briefTitle":1413,"status":71,"phases":1443,"primaryCompletion":1415,"completion":1415,"start":1416,"enrollment":1417,"conditions":1444,"interventions":1445},[43],[33,1057],[1405,1420],{"trials":1447,"activeCount":53},[1448],{"nctId":1424,"briefTitle":1425,"status":71,"phases":1449,"primaryCompletion":1427,"completion":1427,"start":1416,"enrollment":666,"conditions":1450,"interventions":1451},[44],[33,1057],[1405,1420],{"trials":1453,"activeCount":53},[],{"trials":1455,"activeCount":53},[],{"trials":1457,"activeCount":53},[],{"intervention":1459,"totalTrials":8,"cells":1460},"SQ tree SLIT-tablet",{"EARLY_PHASE1":1461,"PHASE1":1463,"PHASE2":1465,"PHASE3":1476,"PHASE4":1478,"NA":1480},{"trials":1462,"activeCount":53},[],{"trials":1464,"activeCount":53},[],{"trials":1466,"activeCount":53},[1467],{"nctId":1468,"briefTitle":1469,"status":71,"phases":1470,"primaryCompletion":1471,"completion":1471,"start":1472,"enrollment":1473,"conditions":1474,"interventions":1475},"NCT02481856","A Dose-response Evaluation of the SQ Tree SLIT-tablet Using an Environmental Exposure Chamber",[44],"2016-04","2015-06",219,[17],[1459],{"trials":1477,"activeCount":53},[],{"trials":1479,"activeCount":53},[],{"trials":1481,"activeCount":53},[],{"intervention":1483,"totalTrials":8,"cells":1484},"AVANZ Cupressus",{"EARLY_PHASE1":1485,"PHASE1":1487,"PHASE2":1489,"PHASE3":1500,"PHASE4":1502,"NA":1504},{"trials":1486,"activeCount":53},[],{"trials":1488,"activeCount":53},[],{"trials":1490,"activeCount":53},[1491],{"nctId":1492,"briefTitle":1493,"status":71,"phases":1494,"primaryCompletion":1495,"completion":1495,"start":1496,"enrollment":1497,"conditions":1498,"interventions":1499},"NCT02069535","An Open Trial to Assess the Tolerability of AVANZ® Cupressus Immunotherapy",[44],"2014-11","2014-04",52,[17],[1483],{"trials":1501,"activeCount":53},[],{"trials":1503,"activeCount":53},[],{"trials":1505,"activeCount":53},[],{"intervention":1507,"totalTrials":8,"cells":1508},"Osiris Phleum pratense",{"EARLY_PHASE1":1509,"PHASE1":1511,"PHASE2":1513,"PHASE3":1523,"PHASE4":1525,"NA":1527},{"trials":1510,"activeCount":53},[],{"trials":1512,"activeCount":53},[],{"trials":1514,"activeCount":53},[1515],{"nctId":1516,"briefTitle":1517,"status":71,"phases":1518,"primaryCompletion":509,"completion":575,"start":904,"enrollment":1519,"conditions":1520,"interventions":1522},"NCT01425788","Comparison of Different Up-dosing Schedules With Osiris Phleum Pratense",[44],236,[1521],"Rhino-conjunctivitis",[1507,1507,1507],{"trials":1524,"activeCount":53},[],{"trials":1526,"activeCount":53},[],{"trials":1528,"activeCount":53},[],{"intervention":1530,"totalTrials":8,"cells":1531},"SLITone ULTRA HDM immunotherapy",{"EARLY_PHASE1":1532,"PHASE1":1534,"PHASE2":1536,"PHASE3":1545,"PHASE4":1547,"NA":1549},{"trials":1533,"activeCount":53},[],{"trials":1535,"activeCount":53},[],{"trials":1537,"activeCount":53},[1538],{"nctId":1539,"briefTitle":1540,"status":71,"phases":1541,"primaryCompletion":1427,"completion":1427,"start":1542,"enrollment":1473,"conditions":1543,"interventions":1544},"NCT01728298","A Dose Response Evaluation of SLITone Ultra HDM Mix Immunotherapy",[44],"2012-11",[20],[1530],{"trials":1546,"activeCount":53},[],{"trials":1548,"activeCount":53},[],{"trials":1550,"activeCount":53},[],{"intervention":1552,"totalTrials":8,"cells":1553},"OSIRIS",{"EARLY_PHASE1":1554,"PHASE1":1556,"PHASE2":1558,"PHASE3":1569,"PHASE4":1571,"NA":1573},{"trials":1555,"activeCount":53},[],{"trials":1557,"activeCount":53},[],{"trials":1559,"activeCount":53},[1560],{"nctId":1561,"briefTitle":1562,"status":782,"phases":1563,"start":143,"enrollment":1564,"conditions":1565,"interventions":1566},"NCT01240954","Comparison of Different Up-dosing Schedules With Osiris",[44],210,[20],[1552,1567,1568],"OSIRIS other concentration 1","OSIRIS other concentration 2",{"trials":1570,"activeCount":53},[],{"trials":1572,"activeCount":53},[],{"trials":1574,"activeCount":53},[],{"intervention":1567,"totalTrials":8,"cells":1576},{"EARLY_PHASE1":1577,"PHASE1":1579,"PHASE2":1581,"PHASE3":1587,"PHASE4":1589,"NA":1591},{"trials":1578,"activeCount":53},[],{"trials":1580,"activeCount":53},[],{"trials":1582,"activeCount":53},[1583],{"nctId":1561,"briefTitle":1562,"status":782,"phases":1584,"start":143,"enrollment":1564,"conditions":1585,"interventions":1586},[44],[20],[1552,1567,1568],{"trials":1588,"activeCount":53},[],{"trials":1590,"activeCount":53},[],{"trials":1592,"activeCount":53},[],{"intervention":1568,"totalTrials":8,"cells":1594},{"EARLY_PHASE1":1595,"PHASE1":1597,"PHASE2":1599,"PHASE3":1605,"PHASE4":1607,"NA":1609},{"trials":1596,"activeCount":53},[],{"trials":1598,"activeCount":53},[],{"trials":1600,"activeCount":53},[1601],{"nctId":1561,"briefTitle":1562,"status":782,"phases":1602,"start":143,"enrollment":1564,"conditions":1603,"interventions":1604},[44],[20],[1552,1567,1568],{"trials":1606,"activeCount":53},[],{"trials":1608,"activeCount":53},[],{"trials":1610,"activeCount":53},[],{"intervention":1612,"totalTrials":8,"cells":1613},"ALK tree AIT 0.5 DU",{"EARLY_PHASE1":1614,"PHASE1":1616,"PHASE2":1618,"PHASE3":1636,"PHASE4":1638,"NA":1640},{"trials":1615,"activeCount":53},[],{"trials":1617,"activeCount":53},[],{"trials":1619,"activeCount":53},[1620],{"nctId":1621,"briefTitle":1622,"status":71,"phases":1623,"primaryCompletion":1624,"completion":1625,"start":1371,"enrollment":1626,"conditions":1627,"interventions":1629},"NCT01675791","A Dose-response Evaluation of ALK (the Sponsor) Tree Allergy Immunotherapy Tablet",[44],"2013-07","2013-09",637,[1628],"Birch Pollen Allergy",[1612,1630,1631,1632,1633,1634,1635],"ALK tree AIT 1 DU","ALK tree AIT 2 DU","ALK tree AIT 4 DU","ALK tree AIT 7 DU","ALK tree AIT 12 DU","ALK tree AIT Placebo",{"trials":1637,"activeCount":53},[],{"trials":1639,"activeCount":53},[],{"trials":1641,"activeCount":53},[],{"intervention":1630,"totalTrials":8,"cells":1643},{"EARLY_PHASE1":1644,"PHASE1":1646,"PHASE2":1648,"PHASE3":1654,"PHASE4":1656,"NA":1658},{"trials":1645,"activeCount":53},[],{"trials":1647,"activeCount":53},[],{"trials":1649,"activeCount":53},[1650],{"nctId":1621,"briefTitle":1622,"status":71,"phases":1651,"primaryCompletion":1624,"completion":1625,"start":1371,"enrollment":1626,"conditions":1652,"interventions":1653},[44],[1628],[1612,1630,1631,1632,1633,1634,1635],{"trials":1655,"activeCount":53},[],{"trials":1657,"activeCount":53},[],{"trials":1659,"activeCount":53},[],{"intervention":1631,"totalTrials":8,"cells":1661},{"EARLY_PHASE1":1662,"PHASE1":1664,"PHASE2":1666,"PHASE3":1672,"PHASE4":1674,"NA":1676},{"trials":1663,"activeCount":53},[],{"trials":1665,"activeCount":53},[],{"trials":1667,"activeCount":53},[1668],{"nctId":1621,"briefTitle":1622,"status":71,"phases":1669,"primaryCompletion":1624,"completion":1625,"start":1371,"enrollment":1626,"conditions":1670,"interventions":1671},[44],[1628],[1612,1630,1631,1632,1633,1634,1635],{"trials":1673,"activeCount":53},[],{"trials":1675,"activeCount":53},[],{"trials":1677,"activeCount":53},[],{"intervention":1632,"totalTrials":8,"cells":1679},{"EARLY_PHASE1":1680,"PHASE1":1682,"PHASE2":1684,"PHASE3":1690,"PHASE4":1692,"NA":1694},{"trials":1681,"activeCount":53},[],{"trials":1683,"activeCount":53},[],{"trials":1685,"activeCount":53},[1686],{"nctId":1621,"briefTitle":1622,"status":71,"phases":1687,"primaryCompletion":1624,"completion":1625,"start":1371,"enrollment":1626,"conditions":1688,"interventions":1689},[44],[1628],[1612,1630,1631,1632,1633,1634,1635],{"trials":1691,"activeCount":53},[],{"trials":1693,"activeCount":53},[],{"trials":1695,"activeCount":53},[],{"intervention":1633,"totalTrials":8,"cells":1697},{"EARLY_PHASE1":1698,"PHASE1":1700,"PHASE2":1702,"PHASE3":1708,"PHASE4":1710,"NA":1712},{"trials":1699,"activeCount":53},[],{"trials":1701,"activeCount":53},[],{"trials":1703,"activeCount":53},[1704],{"nctId":1621,"briefTitle":1622,"status":71,"phases":1705,"primaryCompletion":1624,"completion":1625,"start":1371,"enrollment":1626,"conditions":1706,"interventions":1707},[44],[1628],[1612,1630,1631,1632,1633,1634,1635],{"trials":1709,"activeCount":53},[],{"trials":1711,"activeCount":53},[],{"trials":1713,"activeCount":53},[],{"intervention":1634,"totalTrials":8,"cells":1715},{"EARLY_PHASE1":1716,"PHASE1":1718,"PHASE2":1720,"PHASE3":1726,"PHASE4":1728,"NA":1730},{"trials":1717,"activeCount":53},[],{"trials":1719,"activeCount":53},[],{"trials":1721,"activeCount":53},[1722],{"nctId":1621,"briefTitle":1622,"status":71,"phases":1723,"primaryCompletion":1624,"completion":1625,"start":1371,"enrollment":1626,"conditions":1724,"interventions":1725},[44],[1628],[1612,1630,1631,1632,1633,1634,1635],{"trials":1727,"activeCount":53},[],{"trials":1729,"activeCount":53},[],{"trials":1731,"activeCount":53},[],{"intervention":1635,"totalTrials":8,"cells":1733},{"EARLY_PHASE1":1734,"PHASE1":1736,"PHASE2":1738,"PHASE3":1744,"PHASE4":1746,"NA":1748},{"trials":1735,"activeCount":53},[],{"trials":1737,"activeCount":53},[],{"trials":1739,"activeCount":53},[1740],{"nctId":1621,"briefTitle":1622,"status":71,"phases":1741,"primaryCompletion":1624,"completion":1625,"start":1371,"enrollment":1626,"conditions":1742,"interventions":1743},[44],[1628],[1612,1630,1631,1632,1633,1634,1635],{"trials":1745,"activeCount":53},[],{"trials":1747,"activeCount":53},[],{"trials":1749,"activeCount":53},[],{"intervention":1751,"totalTrials":8,"cells":1752},"oral immunotherapy",{"EARLY_PHASE1":1753,"PHASE1":1755,"PHASE2":1757,"PHASE3":1767,"PHASE4":1769,"NA":1771},{"trials":1754,"activeCount":53},[],{"trials":1756,"activeCount":53},[],{"trials":1758,"activeCount":53},[1759],{"nctId":1760,"briefTitle":1761,"status":71,"phases":1762,"primaryCompletion":1763,"completion":1763,"start":111,"enrollment":1764,"conditions":1765,"interventions":1766},"NCT01191359","Efficacy and Tolerability of Two Different Administration Routes With SLITonePLUS Birch",[44],"2011-01",66,[14],[1751],{"trials":1768,"activeCount":53},[],{"trials":1770,"activeCount":53},[],{"trials":1772,"activeCount":53},[],{"intervention":1774,"totalTrials":8,"cells":1775},"AVANZ Phleum pratense 15,000 SQ+",{"EARLY_PHASE1":1776,"PHASE1":1778,"PHASE2":1780,"PHASE3":1792,"PHASE4":1794,"NA":1796},{"trials":1777,"activeCount":53},[],{"trials":1779,"activeCount":53},[],{"trials":1781,"activeCount":53},[1782],{"nctId":1783,"briefTitle":1784,"status":71,"phases":1785,"primaryCompletion":1786,"completion":1786,"start":1787,"enrollment":1788,"conditions":1789,"interventions":1791},"NCT02166268","Evaluation of the Efficacy and Safety of AVANZ® Phleum Pratense in Grass Pollen-induced Allergic Rhinitis During Controlled Exposure in an Environmental Challenge Chamber",[44],"2015-10","2014-06",140,[1790],"Grass Pollen Induced Allergic Rhinoconjunctivitis",[1774],{"trials":1793,"activeCount":53},[],{"trials":1795,"activeCount":53},[],{"trials":1797,"activeCount":53},[],{"intervention":1799,"totalTrials":8,"cells":1800},"AVANZ Salsola",{"EARLY_PHASE1":1801,"PHASE1":1803,"PHASE2":1805,"PHASE3":1816,"PHASE4":1818,"NA":1820},{"trials":1802,"activeCount":53},[],{"trials":1804,"activeCount":53},[],{"trials":1806,"activeCount":53},[1807],{"nctId":1808,"briefTitle":1809,"status":71,"phases":1810,"primaryCompletion":1811,"completion":152,"start":1812,"enrollment":164,"conditions":1813,"interventions":1815},"NCT02065856","An Open Trial to Assess the Tolerability of AVANZ® Salsola Immunotherapy",[44],"2014-08","2013-12",[1814],"Allergic Rhinoconjunctivitis Due to Salsola Kali Pollen",[1799],{"trials":1817,"activeCount":53},[],{"trials":1819,"activeCount":53},[],{"trials":1821,"activeCount":53},[],{"intervention":1823,"totalTrials":8,"cells":1824},"Specific allergen immunotherapy",{"EARLY_PHASE1":1825,"PHASE1":1827,"PHASE2":1829,"PHASE3":1841,"PHASE4":1843,"NA":1845},{"trials":1826,"activeCount":53},[],{"trials":1828,"activeCount":53},[],{"trials":1830,"activeCount":53},[1831],{"nctId":1832,"briefTitle":1833,"status":71,"phases":1834,"primaryCompletion":1835,"completion":1836,"start":153,"enrollment":1837,"conditions":1838,"interventions":1840},"NCT00987909","Exposure Chamber Trial With Cat Immunotherapy",[44],"2010-03","2010-05",60,[1839],"Cat Allergy",[1823,1823,1823,1823],{"trials":1842,"activeCount":53},[],{"trials":1844,"activeCount":53},[],{"trials":1846,"activeCount":53},[],{"intervention":1848,"totalTrials":8,"cells":1849},"Peanut SLIT-tablet",{"EARLY_PHASE1":1850,"PHASE1":1852,"PHASE2":1854,"PHASE3":1867,"PHASE4":1869,"NA":1871},{"trials":1851,"activeCount":53},[],{"trials":1853,"activeCount":53},[],{"trials":1855,"activeCount":53},[1856],{"nctId":1857,"briefTitle":1858,"status":71,"phases":1859,"primaryCompletion":1860,"completion":1861,"start":1862,"enrollment":1863,"conditions":1864,"interventions":1866},"NCT05440643","Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy",[43,44],"2026-03-10","2026-04-05","2022-09-07",209,[1865],"Peanut Allergy",[1848],{"trials":1868,"activeCount":53},[],{"trials":1870,"activeCount":53},[],{"trials":1872,"activeCount":53},[],{"intervention":1874,"totalTrials":8,"cells":1875},"Betula Verrucosa allergen extract",{"EARLY_PHASE1":1876,"PHASE1":1878,"PHASE2":1886,"PHASE3":1888,"PHASE4":1890,"NA":1892},{"trials":1877,"activeCount":53},[],{"trials":1879,"activeCount":53},[1880],{"nctId":1881,"briefTitle":1882,"status":71,"phases":1883,"primaryCompletion":299,"start":131,"conditions":1884,"interventions":1885},"NCT00535639","Tolerability of ALK Tree Tablet",[43],[14],[1874],{"trials":1887,"activeCount":53},[],{"trials":1889,"activeCount":53},[],{"trials":1891,"activeCount":53},[],{"trials":1893,"activeCount":53},[],{"intervention":1895,"totalTrials":8,"cells":1896},"ALK Ragweed",{"EARLY_PHASE1":1897,"PHASE1":1899,"PHASE2":1908,"PHASE3":1910,"PHASE4":1912,"NA":1914},{"trials":1898,"activeCount":53},[],{"trials":1900,"activeCount":53},[1901],{"nctId":1902,"briefTitle":1903,"status":71,"phases":1904,"start":278,"enrollment":1905,"conditions":1906,"interventions":1907},"NCT00330083","Safety of ALK Ragweed Tablet",[43],72,[14],[1895],{"trials":1909,"activeCount":53},[],{"trials":1911,"activeCount":53},[],{"trials":1913,"activeCount":53},[],{"trials":1915,"activeCount":53},[],{"intervention":1917,"totalTrials":8,"cells":1918},"Tablet, Dispersible",{"EARLY_PHASE1":1919,"PHASE1":1921,"PHASE2":1923,"PHASE3":1925,"PHASE4":1927,"NA":1929},{"trials":1920,"activeCount":53},[],{"trials":1922,"activeCount":53},[],{"trials":1924,"activeCount":53},[],{"trials":1926,"activeCount":53},[],{"trials":1928,"activeCount":53},[],{"trials":1930,"activeCount":53},[1931],{"nctId":1932,"briefTitle":1933,"status":71,"phases":1934,"primaryCompletion":1935,"completion":1935,"start":1936,"enrollment":1937,"conditions":1938,"interventions":1939},"NCT03746860","N.I.S of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in France",[],"2020-09-29","2018-05-09",1508,[26,87,88],[1917],{"intervention":1941,"totalTrials":8,"cells":1942},"Allergy immunotherapy",{"EARLY_PHASE1":1943,"PHASE1":1945,"PHASE2":1947,"PHASE3":1949,"PHASE4":1951,"NA":1953},{"trials":1944,"activeCount":53},[],{"trials":1946,"activeCount":53},[],{"trials":1948,"activeCount":53},[],{"trials":1950,"activeCount":53},[],{"trials":1952,"activeCount":53},[],{"trials":1954,"activeCount":53},[1955],{"nctId":1956,"briefTitle":1957,"status":71,"phases":1958,"primaryCompletion":1959,"completion":1959,"start":1960,"enrollment":1961,"conditions":1962,"interventions":1964},"NCT04125888","Impact of AIT on Allergic Rhinitis and Asthma",[],"2021-04-16","2019-07-22",92048,[14,1963],"Respiratory Disease",[1941],{"intervention":1966,"totalTrials":8,"cells":1967},"SQ SLIT-tablet",{"EARLY_PHASE1":1968,"PHASE1":1970,"PHASE2":1972,"PHASE3":1974,"PHASE4":1976,"NA":1978},{"trials":1969,"activeCount":53},[],{"trials":1971,"activeCount":53},[],{"trials":1973,"activeCount":53},[],{"trials":1975,"activeCount":53},[],{"trials":1977,"activeCount":53},[],{"trials":1979,"activeCount":53},[1980],{"nctId":1981,"briefTitle":1982,"status":1983,"phases":1984,"primaryCompletion":1985,"completion":1985,"start":1986,"enrollment":1987,"conditions":1988,"interventions":1989},"NCT05476484","Comparative Real World Effectiveness of SQ Sublingual Immunotherapy (SLIT)-Tablets vs. Controls in Allergic Rhinitis and Asthma","UNKNOWN",[],"2024-06","2022-04-01",49844,[14,20,31],[1966],{"intervention":1991,"totalTrials":8,"cells":1992},"Standardised allergen extract from house dust mites",{"EARLY_PHASE1":1993,"PHASE1":1995,"PHASE2":1997,"PHASE3":1999,"PHASE4":2001,"NA":2003},{"trials":1994,"activeCount":53},[],{"trials":1996,"activeCount":53},[],{"trials":1998,"activeCount":53},[],{"trials":2000,"activeCount":53},[],{"trials":2002,"activeCount":53},[],{"trials":2004,"activeCount":53},[2005],{"nctId":2006,"briefTitle":2007,"status":1983,"phases":2008,"primaryCompletion":2009,"completion":2010,"start":2011,"enrollment":2012,"conditions":2013,"interventions":2014},"NCT06151938","Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis",[],"2025-05-20","2025-08-20","2023-11-21",100,[26,254],[1991]]